US 11,787,874 B2
Factor X binders enhancing FX activation
Jacob Lund, Roskilde (DK); Karina Thorn, Farum (DK); Mikkel Nors Harndahl, Roskilde (DK); Marie-Ange Buyse, Merelbeke (BE); Evelyn De Tavernier, Deurle (BE); and Soren Steffensen, Etterbeek (BE)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Appl. No. 16/764,124
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
PCT Filed Nov. 15, 2018, PCT No. PCT/EP2018/081296
§ 371(c)(1), (2) Date May 14, 2020,
PCT Pub. No. WO2019/096874, PCT Pub. Date May 23, 2019.
Claims priority of application No. 17201762 (EP), filed on Nov. 15, 2017; and application No. 18174634 (EP), filed on May 28, 2018.
Prior Publication US 2021/0054097 A1, Feb. 25, 2021
Int. Cl. C07K 16/36 (2006.01)
CPC C07K 16/36 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/35 (2013.01); C07K 2317/569 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 7 Claims
 
1. A single domain antibody capable of binding FX,
comprising SEQ ID NO:8, 9, 10, 11, 54, 55, 56 or 57, respectively; or
comprising the three CDRs of SEQ ID NO:8, 9, 10, 11, 54, 55, 56 or 57, respectively.